Patrik Brundin, MD, PhD, has published over 325 papers on Parkinson's disease (PD) and related topics. In 1988, he obtained his PhD at Lund University, Sweden on intracerebral transplantation in PD. He was part of the team that reported evidence on the survival and function of transplants in PD in 1990, and, in 1992, he obtained an MD at Lund University. In 2008, his team described Lewy bodies in grafted dopamine neurons and suggested that a prion-like mechanism operates in PD. He leads the Center for Neurodegenerative Science at the Van Andel Research Institute and his research team is focused on experimental models and novel therapies in PD. Dr. Brundin is one of the most cited scientists in neurodegenerative disease, with a focus on Parkinson's, and has received numerous awards for his work. He is the co-editor-in-chief of the Journal of Parkinson's Disease and is a consultant for several biotechnological and pharmaceutical companies.
Associated Grants
-
-
Upregulation of Autophagy by Tet3-mediated 5-methylcytosine oxidation – Relevance to Parkinson's Disease
2016
-
Validating the Neuroprotective Enzyme ACMSD as a Novel Therapeutic Target in Parkinson's Disease by Viral Vector-Mediated Overexpression
2015
-
Targeting Internalization and Aggregation of Alpha-synuclein Proteopathic Seeds with Glycosaminoglycan Interacting Small Molecules (GISMO)
2014